Eli Lilly (LLY) To Acquire Dice Therapeutics (DICE)

Schwab Network

Eli Lilly (LLY) is acquiring Dice Therapeutics (DICE). Damien Conover discusses this as LLY is purchasing DICE for $48 per share cash. DICE is a biopharmaceutical company that leverages its proprietary delscape technology platform to develop novel oral therapeutic candidates. The board of directors for both companies have approved the transaction, and the transaction is expected to close in 3Q. Damien talks about the key takeaways from LLY's acquisition of DICE. He then goes over pharma trends to watch. Tune in to find out more about the stock market today.